Arnadottir M, Hultberg B, Berg A L
Department of Medicine, National University Hospital, Reykjavik, Iceland.
Nephrol Dial Transplant. 2001 Jan;16(1):45-7. doi: 10.1093/ndt/16.1.45.
The atherothrombotic risk pattern of the nephrotic syndrome resembles that of hyperhomocysteinemia. However, the effect of nephrotic range proteinuria on homocysteine metabolism has never been studied.
The study included 11 male nephrotic patients with idiopathic membranous nephropathy who underwent a treatment trial with adrenocorticotrophic hormone and 11 male non-nephrotic, renal function-matched control subjects. The nephrotic patients were studied before and after the treatment, which induced a marked reduction in urinary protein excretion and a moderate improvement in renal function in all cases.
Plasma total homocysteine (tHcy) concentration did not change significantly during treatment, whereas the nephrotic patients had significantly lower tHcy than the non-nephrotic patients (14.2 +/- 3.4 micromol/l vs 19.0 +/- 5.4 micromol/l). tHcy correlated significantly with serum concentrations of creatinine (r = 0.53, P < 0.05) and albumin (r = 0.43, P < 0.05), glomerular filtration rates (GFRs) (iohexol clearances) (r = -0.42, P < 0.05) and urinary albumin excretion (r = -0.47, P < 0.05).
The expected tHcy-lowering effect of improved renal function may have masked a tHcy-elevating effect due to reduced proteinuria leading to no net change in tHcy during treatment. The notion of an increase in tHcy associated with remission of the nephrotic syndrome is in accordance with the significantly lower tHcy in the nephrotic renal patients compared with the non-nephrotic renal function-matched patients, and the relationships between tHcy and serum albumin concentrations as well as urinary albumin excretion. Thus, the results of this small study suggest that nephrotic range proteinuria directs homocysteine metabolism towards a decrease in tHcy. However, the findings need to be confirmed in larger patient populations and in different varieties of the nephrotic syndrome.
肾病综合征的动脉粥样硬化血栓形成风险模式类似于高同型半胱氨酸血症。然而,肾病范围蛋白尿对同型半胱氨酸代谢的影响从未被研究过。
该研究纳入了11例患有特发性膜性肾病的男性肾病患者,他们接受了促肾上腺皮质激素治疗试验,以及11例肾功能匹配的男性非肾病对照受试者。对肾病患者在治疗前后进行了研究,治疗使所有病例的尿蛋白排泄显著减少,肾功能有中度改善。
治疗期间血浆总同型半胱氨酸(tHcy)浓度无显著变化,而肾病患者的tHcy显著低于非肾病患者(14.2±3.4微摩尔/升对19.0±5.4微摩尔/升)。tHcy与血清肌酐浓度(r = 0.53,P < 0.05)、白蛋白浓度(r = 0.43,P < 0.05)、肾小球滤过率(GFR)(碘海醇清除率)(r = -0.42,P < 0.05)及尿白蛋白排泄(r = -0.47,P < 0.05)显著相关。
肾功能改善预期的降低tHcy的作用可能掩盖了因蛋白尿减少导致的tHcy升高作用,从而使治疗期间tHcy无净变化。同型半胱氨酸升高与肾病综合征缓解相关的观点与肾病患者的tHcy显著低于肾功能匹配的非肾病患者以及tHcy与血清白蛋白浓度和尿白蛋白排泄之间的关系相符。因此,这项小型研究的结果表明,肾病范围蛋白尿使同型半胱氨酸代谢朝着降低tHcy的方向发展。然而,这些发现需要在更大的患者群体和不同类型的肾病综合征中得到证实。